Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting

Inclusion Criteria:

- Diagnosis of any form of Primary Immunodeficiency Disease

- Males and Females

- ≥ 15 and ≤ 85 years of age

- 5% treatment Naïve IVIg for the treatment of PIDD

- Ability to have Gammaplex® IVIg prescribed under the discretion of the patient's
treating physician in accordance with standard treatment practices for the entire
duration of the study

- Ability and willingness to provide informed consent and comply with study requirements
and procedures

- Ability to read and write English

- Understanding of study procedures and ability to comply with study procedures for the
entire length of the study

- Eligible for infusion services by AxelaCare Health Solutions, LLC, in collaboration
with the subject's prescribing physician and insurance provider

Exclusion Criteria:

- The presence of any medical condition that the investigator and/or prescribing
physician deems incompatible with participation in this trial.

- Prisoners, and other wards of the state

- Determined to have non-competency of data collection requirements (physical
assessments and use of an iPAD™) by either the home infusion nurse and/or Caregiver.

- Receiving Subcutaneous Immunoglobulin (SCIg) Therapy during study participation.